Effectiveness and Safety of Restylane Lyft Lidocaine for Jawline Definition
NCT ID: NCT05622812
Last Updated: 2025-03-07
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
140 participants
INTERVENTIONAL
2023-02-16
2024-06-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Effectiveness of Restylane Lyft With Lidocaine for Augmentation of the Chin Region to Improve the Chin Profile
NCT05777759
Safety and Effectiveness of GP0112 for Cheek Augmentation and Correction of Midface Contour Deficiencies
NCT05262777
Effectiveness and Safety of Restylane Lyft With Lidocaine in the Dorsal Hand
NCT02650921
Injection Technique Assessment of Restylane Lyft With Lidocaine for Cheek Augmentation
NCT03160716
Restylane + Lidocaine and Restylane Lyft for the Treatment of Nasolabial Folds
NCT04174131
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
A parallel study: two or more groups of participants receive different interventions. Trial participants are assigned to one of the treatment arms at the beginning of the trial and remain in that trial arm throughout the length of the trial. A randomized group is usually assigned.
TREATMENT
SINGLE
Investigator blinding will be accomplished by having a Treating Investigator administer the treatments and having a Blinded Evaluator, to whom randomization and treatment are concealed, conduct blinded assessments. Safety assessments will be performed by non-blinded personnel.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment group
Initial Restylane Lyft Lidocaine injection and one optional touch-up treatment at 1 month after treatment
Restylane Lyft Lidocaine
Treatment for Jawline definition
No-treatment control group
Optional treatment will be administered at 12 months
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Restylane Lyft Lidocaine
Treatment for Jawline definition
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Consent the use of facial images for marketing purposes and educational material
* Subject with moderate to very severe (Grade 2 to 4) on the GJS
* Subject is willing to abstain from any other facial, submental, and/or neck aesthetic procedure(s) or implant
* Female of childbearing potential with a negative urine pregnancy test before treatment
Exclusion Criteria
* Subjects presenting with known/previous allergy or hypersensitivity to streptococcal proteins
* Subject with bleeding disorders or taking thrombolytics or anticoagulants
* Prior surgical procedure in the treatment area
* History of other facial treatment/procedure in the previous 6 months HA in or near the intended treatment site
* Presence of any disease or lesions near or on the area to be treated
* Presence of any condition, in the opinion of the Treating Investigator, makes the subject unable to complete the study per protocol
* Women who are pregnant or breast feeding, or women of childbearing potential who are not practicing adequate contraception or planning to become pregnant during the study period
* Study site personnel, close relatives of the study site personnel, employees, or close relatives of employees at the Sponsor Company
* Participation in any other interventional clinical study within 30 days before treatment
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Galderma R&D
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Galderma R&D
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Galderma Research Site
Vancouver, British Columbia, Canada
Galderma Research Site
Vancouver, British Columbia, Canada
Galderma Research Site
Burlington, Ontario, Canada
Galderma Research Site
London, Ontario, Canada
Galderma Research Site
Oakville, Ontario, Canada
Galderma Research Site
Toronto, Ontario, Canada
Galderma Research Site
Windsor, Ontario, Canada
Galderma Research Site
Woodbridge, Ontario, Canada
Galderma Research Site
Westmount, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
05DF2209
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.